Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Metrics to compare | PHGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHGNPeersSector | |
---|---|---|---|---|
P/E Ratio | −135.1x | −2.9x | −0.6x | |
PEG Ratio | −3.88 | 0.00 | 0.00 | |
Price/Book | 4.6x | 2.5x | 2.6x | |
Price / LTM Sales | 3.3x | 10.2x | 3.4x | |
Upside (Analyst Target) | - | 111.5% | 35.5% | |
Fair Value Upside | Unlock | 4.3% | 3.7% | Unlock |